NEWS

PRESS RELEASES

October 30, 2023

Gravitas Announces Asset Sale of GR-2397 Antifungal to Basilea Pharmaceutica Ltd

January 4, 2022

Gravitas Appoints Bill Enright to its Board of Directors

December 7, 2021

Gravitas Purchases GR-2397 for Treatment of Severe Fungal Infections



EVENTS

June 13-16, 2022, San Diego, California

BIO International Convention / One-on-One Partnering Forum


October 19-23, 2022, Washington, D.C.

IDWeek / Registered Attendee